etoposide

Overview

Podophyllotoxin-derivative topoisomerase II inhibitor; included in CHOEP/EPOCH variants of CHOP-based lymphoma therapy.

Evidence in the corpus

  • 45% of the 132 MSK nodal PTCL cohort received CHOEP/EPOCH (cyclophosphamide/doxorubicin/vincristine/prednisone plus etoposide); TP53 mutation status predicted markedly inferior PFS on these etoposide-containing regimens (HR 3.1, P=.005) PMID:37078708.
  • Etoposide is among the NCCN-listed regimens that recurred as top-five PDTO responders for osteosarcoma (OS) in a functional precision-medicine screen of 92 sarcoma patient-derived tumor organoids (PDTOs). In three treatment-naïve osteosarcoma biopsies, MAP regimen (methotrexate/doxorubicin/cisplatin) organoid response tracked post-resection necrosis and recurrence outcomes PMID:39305899.
  • EWS::FLI1-transduced human embryonic mesenchymal stem cells showed >2-fold greater sensitivity to etoposide than controls, linked to impaired ATM/ATR phosphorylation and elevated basal DNA damage despite paradoxically elevated BRCA1 expression PMID:25186949
  • Used as part of ICE induction chemotherapy (idarubicin+cytarabine+etoposide) in three AMLSG intensive-therapy trials for AML (n=1540); treatment backbone for the genomic subgrouping study PMID:27276561
  • Used in BEP (bleomycin+etoposide+cisplatin) first-line regimen in 37.2% of 180 advanced GCT patients in cisplatin-resistance biomarker study PMID:27646943
  • Used in cisplatin/etoposide combination chemotherapy in SCLC PDX models; EZH2 inhibitor EPZ011989 re-sensitized chemoresistant models to etoposide by restoring SLFN11 expression via H3K27me3 removal PMID:28196596.
  • Component of ISG/SSG IV protocol (vincristine, doxorubicin, ifosfamide, etoposide) given to a patient with EWSR1::BEND2 bladder sarcoma; intravesical tumor resolved after 2 months but pelvic and pulmonary metastases did not respond PMID:28199314.
  • Etoposide-cisplatin regimens (as used for neuroendocrine tumors) are proposed for MIBC neuronal subtype (5% of cohort; worst survival, TP53+RB1 co-mutation in 50%, often lacking histopathologic NE features) in neoadjuvant or metastatic settings PMID:28988769

Resistance mechanisms

  • TP53 mutations and 17p deletions correlate with inferior PFS on CHOP/CHOEP-based induction PMID:37078708.

Cancer types (linked)

  • PTCL, AITL, ALCL
  • OS — osteosarcoma (NCCN-listed, observed in PDTO functional screen)

Sources

This page was processed by entity-page-writer on 2026-05-01. - PMID:25186949

This page was processed by wiki-cli on 2026-05-11. - PMID:27276561

This page was processed by wiki-cli on 2026-05-14. - PMID:27646943

This page was processed by wiki-cli on 2026-05-14. - PMID:28196596

This page was processed by wiki-cli on 2026-05-14. - PMID:28199314

This page was processed by wiki-cli on 2026-05-14. - PMID:28988769

This page was processed by wiki-cli on 2026-05-15.